Basic characteristics | No. of systematic reviews (N = 127) |
---|---|
Year | |
2015–2017 | 81 (63.78%) |
2018–2019 (4 published in 2020 were online first in 2019) | 46 (36.22%) |
Region of corresponding author | |
America (North and South) | 32 (25.20%) |
Asia | 35 (27.56%) |
European | 54 (42.52%) |
Oceania | 6 (4.72%) |
Reporting guideline claimed by review authors | |
PRISMA | 64 (50.39%) |
MOOSE | 5 (3.94%) |
Cochrane Handbooka | 3 (2.36%) |
PRISMA and MOOSE | 1 (0.79%) |
PRISMA-Pa | 1 (0.79%) |
No | 53 (41.73%) |
Use of AMSTAR tool | |
Yes | 5 (3.94%) |
No | 122 (96.06%) |
Language | |
English | 125 (98.43%) |
Other languages | 2 (1.57%) |
Type of systematic reviews | |
Quantitative review (with meta-analysis) | 96 (75.59%) |
Narrative review (without meta-analysis) | 31 (24.41%) |
Type of study for meta-analysis | |
Randomized controlled trial (RCT) | 47 (37.01%) |
Non-randomized study of intervention (NRSI) | 25 (19.69%) |
Both RCT and NRSI | 46 (36.22%) |
Not reported | 9 (7.09%) |
Study number (Median, first and third quartiles) | 14 (8 to 28) |
2–10 | 48 (37.80%) |
11–20 | 36 (28.35%) |
21–30 | 18 (14.17%) |
> 30 | 25 (19.69) |
Funding | |
Non-profit | 28 (22.05%) |
Profit | 2 (1.57%) |
Not funded | 58 (45.67%) |
Not reported | 39 (30.71%) |
Use of GRADE | |
Yes | 13 (10.24%) |
No | 1144 (89.76%) |